European Commission grants Lilly and Boehringer Ingelheim’s insulin glargine product marketing authorisation in Europe

Lilly/Boehringer Ingelheim’s insulin glargine product is the first insulin treatment approved through the European Medicines Agency’s biosimilar pathway and the fourth diabetes product approved in the EU from the Lilly-Boehringer Ingelheim Alliance